# Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome

> **NCT02858453** · PHASE3 · UNKNOWN · sponsor: **Aquinox Pharmaceuticals (Canada) Inc.** · enrollment: 433 (actual)

## Conditions studied

- Interstitial Cystitis
- Bladder Pain Syndrome
- Painful Bladder Syndrome
- Chronic Interstitial Cystitis

## Interventions

- **DRUG:** AQX-1125 100 mg
- **DRUG:** AQX-1125 200 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02858453
- **Lead sponsor:** Aquinox Pharmaceuticals (Canada) Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-07
- **Primary completion:** 2018-08
- **Final completion:** 2020-02
- **Target enrollment:** 433 (ACTUAL)
- **Last updated:** 2018-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02858453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02858453, "Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02858453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*